Related references
Note: Only part of the references are listed.Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
Myron S. Czuczman et al.
BLOOD (2012)
Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
Jamie Honeychurch et al.
BLOOD (2012)
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
Gilles Salles et al.
BLOOD (2012)
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
Matthew J. Barth et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia
Hong Ma et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
Myron S. Czuczman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
Michinori Ogura et al.
CANCER SCIENCE (2012)
Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Andres Forero-Torres et al.
CLINICAL CANCER RESEARCH (2012)
Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies
Antonio Gualberto
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion
Viola Biberacher et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia
Craig Reynolds et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies
Robert M. Sharkey et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Anti-CD22 therapy in acute lymphoblastic leukaemia
Dieter Hoelzer
LANCET ONCOLOGY (2012)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2012)
Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22
Weihsu C. Chen et al.
LEUKEMIA & LYMPHOMA (2012)
Bendamustine: more ammunition in the battle against mantle cell lymphoma
Julie E. Chang et al.
LEUKEMIA & LYMPHOMA (2012)
R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma
Yuko Mishima et al.
EXPERIMENTAL HEMATOLGY & ONCOLOGY (2012)
Digitoxin and its analogs as novel cancer therapeutics
Hosam A. Elbaz et al.
EXPERIMENTAL HEMATOLGY & ONCOLOGY (2012)
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
William G. Wierda et al.
BLOOD (2011)
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
William G. Wierda et al.
BLOOD (2011)
The future of anti-CD20 monoclonal antibodies: are we making progress?
Waleed Alduaij et al.
BLOOD (2011)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
Kensei Tobinai et al.
CANCER SCIENCE (2011)
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Veronique Blanc et al.
CLINICAL CANCER RESEARCH (2011)
The Four types of Tregs in malignant lymphomas
Jing Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
Z. L. Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission
Franz Buchegger et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
Christian Recher et al.
LANCET (2011)
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
Bertrand Coiffier et al.
LANCET ONCOLOGY (2011)
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2010)
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia
Samantha M. Jaglowski et al.
BLOOD (2010)
Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope
Susumu Uchiyama et al.
CANCER SCIENCE (2010)
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Nicole M. Okeley et al.
CLINICAL CANCER RESEARCH (2010)
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
Bruce D. Cheson
JOURNAL OF CLINICAL ONCOLOGY (2010)
Targeted therapy in lymphoma
Patrick B. Johnston et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
The clinical potential of microRNAs
Anuradha Budhu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Role of Wnt canonical pathway in hematological malignancies
G. E. Xueling et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Jiahuai Tan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects
David M. Goldenberg et al.
LEUKEMIA & LYMPHOMA (2010)
The future of CD20 monoclonal antibody therapy in B-cell malignancies
Myron S. Czuczman et al.
LEUKEMIA & LYMPHOMA (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
CD20-Targeted Therapy: The Next Generation of Antibodies
Tom van Meerten et al.
SEMINARS IN HEMATOLOGY (2010)
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma
B. Esmaeli et al.
ANNALS OF ONCOLOGY (2009)
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
David T. Teachey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
Thomas M. Habermann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Histone deacetylase inhibitors as anti-neoplastic agents
Nicolas Batty et al.
CANCER LETTERS (2009)
Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
Ayad M. Al-Katib et al.
CLINICAL CANCER RESEARCH (2009)
Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial
Angelika Bischof Delaloye et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study
Oliver Weigert et al.
LEUKEMIA & LYMPHOMA (2009)
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma
J. H. Mendler et al.
ANNALS OF ONCOLOGY (2008)
Exploiting the mammalian target of rapamycin pathway in hematologic malignancies
Jessica K. Altman et al.
CURRENT OPINION IN HEMATOLOGY (2008)
Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma
Victor Y. Yazbeck et al.
EXPERIMENTAL HEMATOLOGY (2008)
Lenalidomide for the treatment of B-cell malignancies
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
STAT3: A critical transcription activator in angiogenesis
Zhong Chen et al.
MEDICINAL RESEARCH REVIEWS (2008)
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
Manzurul A. Sikder et al.
Current Hematologic Malignancy Reports (2008)
Rituximab therapy in malignant lymphoma
B. Coiffier
ONCOGENE (2007)
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206
Kristie A. Blum et al.
LEUKEMIA & LYMPHOMA (2007)
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)
Sven Trelle et al.
HAEMATOLOGICA (2007)
Proteasome inhibition as a new therapeutic principle in hematological malignancies
Constantine S. Mitsiades et al.
CURRENT DRUG TARGETS (2006)
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W. L. Yee et al.
CLINICAL CANCER RESEARCH (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and anaplastic large cell lymphomas
F Jundt et al.
BLOOD (2005)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
R Stein et al.
CLINICAL CANCER RESEARCH (2004)
STAT proteins as novel targets for cancer drug discovery
J Turkson
EXPERT OPINION ON THERAPEUTIC TARGETS (2004)
Rituximab - A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
GL Plosker et al.
DRUGS (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
